In 92 adults with narcolepsy type 1, once-daily alixorexton 4, 6 or 8 mg for 6 weeks improved Maintenance of Wakefulness Test sleep latency versus placebo by 22.2, 24.1 and 26.0 min (all adjusted p<0.01). Frequent urination (55%) and insomnia (28%) were common.
RCTn = 92
Plazzi et al. Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial